Press Release
12 Jan 2026
Spring Sciences Australia (SSA), a leading producer of pharmaceutical-grade medicinal cannabis, has announced a strategic partnership with Union Cannabis Group (UCG) Inc., a United States-based pioneer in hydrocarbon cannabis extraction, automation, and formulation technologies.
The partnership will accelerate the establishment of Australia’s most advanced extraction and manufacturing ecosystem, enabling SSA to produce a full spectrum of premium cannabis concentrates, vapes, and infused products for regulated medical markets domestically and abroad.
Under the agreement, UCG Inc., the extraction and operational team behind Dabstract, one of America’s most awarded cannabis brands, will provide SSA with proprietary Standard Operating Procedures (SOPs), patented technologies, and technical consultancy to commission high-throughput extraction lines capable of delivering unparalleled efficiency, consistency, and purity.
SSA Managing Director Dr. Steve Newbery commented on the significance of the deal:
"This collaboration marks a transformative moment for SSA. UCG’s engineering expertise and operational systems are globally recognised for their precision and scalability. Together, we’re establishing a pharmaceutical-grade platform that positions Australia as a regional leader in manufactured cannabis products.”
With operations spanning multiple US jurisdictions and a global reputation for technical innovation, terpene integrity, and process efficiency, UCG Inc. brings over a decade of experience optimising solvent-based extraction at industrial scale. The company’s technology portfolio is engineered to remain true to the strain, true to the flower, preserving cannabinoid and terpene fidelity while achieving repeatable pharmaceutical-grade outcomes.
Eli Korer, Co-Founder of UCG Inc., commented:
“Our mission has always been to bring scientific precision and scalability to cannabis extraction. Partnering with SSA allows us to extend that philosophy to one of the world’s most advanced medical cannabis markets. SSA’s pharmaceutical discipline, automation, and regulatory alignment make them the ideal partner to deliver next-generation products with global export potential.”
The integration of UCG’s extraction systems into SSA’s Caboolture facility will create one of the most efficient and compliant cannabis manufacturing hubs in the Southern Hemisphere, aligned with GACP, GMP, and TGO 93 standards, and designed to meet the expectations of both patients and capital markets.
The partnership forms a cornerstone of SSA’s strategic roadmap toward international expansion, supporting key initiatives such as the Clean Flower Initiative and future pharmaceutical formulations pipeline.
Key benefits of the collaboration include:
· Deployment of UCG’s patented hydrocarbon extraction and formulation systems within SSA’s GMP-aligned facility.
· High-efficiency production of live resin vapes, concentrates, and infused formats for domestic and export markets.
· Strengthened pharmaceutical compliance and scalability for future product diversification.
· Foundation for Australia’s first integrated cannabis extraction and manufacturing hub focused on clinical integrity and commercial readiness.
Through this partnership, SSA and UCG Inc. aim to redefine efficiency, safety, and pharmaceutical precision in medicinal cannabis, setting a new benchmark for manufacturing excellence in the Asia-Pacific region.
Contact Information
For media inquiries, please contact:
Spring Sciences Australia Ltd
info@springsciences.com.au